CARDIFF ONCOLOGY, INC. Current Assets
CARDIFF ONCOLOGY, INC. (CRDF) had Current Assets of $35.59 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-11
- 2026-06-30: Assets, Current $35.59M.
- 2026-03-31: Assets, Current $47.34M.
- 2025-12-31: Assets, Current $60.13M.
- 2025-09-30: Assets, Current $61.80M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $35.59M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $47.34M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $60.13M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $61.80M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $73.70M 10-Q · filed 2025-07-29 | |
| 2025-03-31 | $82.71M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $95.05M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $59.33M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $62.25M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $69.99M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $77.41M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $83.91M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $92.73M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $101.75M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $111.28M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $119.75M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $127.41M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $135.81M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $146.13M 10-K · filed 2023-03-02 | |
| 2021-09-30 | $137.77M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $142.87M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $128.57M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $133.36M 10-K · filed 2022-02-24 | $133.36M 10-K · filed 2021-02-25 |
| 2020-09-30 | $38.19M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $28.82M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $10.28M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $11.35M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $9.98M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $11.82M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $12.34M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $12.77M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $16.04M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $19.64M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $7.84M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $9.47M 10-K · filed 2019-03-06 | |
| 2017-09-30 | $8.55M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $8.66M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $29.73M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $38.95M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $47.98M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $51.62M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $60.89M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $68.38M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $74.82M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $41.90M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $44.47M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $27.72M 10-K · filed 2016-03-10 | |
| 2014-09-30 | $31.57M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $35.03M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $23.26M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $26.07M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $28.00M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $8.52M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $9.35M 10-Q · filed 2013-05-14 | |
| 2012-12-31 | $11.05M 10-K · filed 2014-03-17 | |
| 2012-09-30 | $8.00M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $9.44M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $705.75K 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $842.17K 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |